Patient P-01845
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −28% vs expected — Dietary Support Protocol NP-02
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 66 ME-01 recommended — Monitoring Escalation ME-01
- Day 67 Patient accepted — Started ME-01 in the companion
- Day 70 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- Treatment adherence+8
- GI instability+7
- Nutritional resilience-7
- Inflammatory activity+6
- Toxicity+5
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −28%
- Monitoring Escalation ME-01Day 66Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 60 and rising
- WearableSleep 5.4 h, below personal baseline
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 56
- Autonomic recovery ↓45
- WearableResting HR 84 bpm
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 62
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 43/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 6.1 h
- Steps
- 7,859
- Resting HR
- 80 bpm
Daily log: GI score 60, nutritional resilience 32, adherence 54.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01436 | 51% | S14 | GI-04 | improved | 38 |
| P-01842 | 51% | S14 | NP-02 | improved | 55 |
| P-01389 | 49% | S14 | SC-12 | improved | 46 |
| P-01412 | 47% | S14 | NP-02 | improved | 49 |
| P-01413 | 47% | S14 | GI-04 | improved | 44 |
| P-01505 | 47% | S14 | NP-02 | improved | 41 |
| P-01728 | 47% | S14 | SC-12 | improved | 41 |
| P-01539 | 46% | S14 | GI-04 | improved | 43 |
| P-01581 | 46% | S18 | GI-04 | improved | 51 |
| P-01356 | 45% | S14 | GI-04 | improved | 42 |
| P-01675 | 45% | S14 | NP-02 | improved | 38 |
| P-01720 | 45% | S14 | NP-02 | improved | 47 |